LivaNova Announces RECOVER Clinical Study Shows Meaningful Benefits Of It's VNS Therapy System In Select Secondary Endpoints For Unipolar Patients With Treatment-Resistant Depression; Results Published In Two Articles In 'Brain Stimulation'

BenzingaDec 18 08:44 ET

Express News | LivaNova PLC - Active Treatment Arm Showed Significant Improvement Despite Primary Endpoint Not Met

ReutersDec 18 08:34 ET

Express News | Recover Clinical Study Shows Meaningful Benefits of Livanova’s Vns Therapy System in Select Secondary Endpoints for Unipolar Patients With Treatment-Resistant Depression

ReutersDec 18 08:30 ET

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients With Treatment-Resistant Depression

BusinesswireDec 18 08:30 ET

"Laggard" Stocks With Expanding FCF Margins and Attractive FCF Yields – Goldman

Seeking AlphaDec 5 13:43 ET

LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting

BusinesswireDec 5 09:00 ET